DB
INBX

Dmitry Balyasny’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Dmitry Balyasny’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,861
Closed -$236K – 3054
2023
Q3 		$236K Buy
+12,861
New +$269K ﹤0.01% 1984
2023
Q1 		– Sell
-11,344
Closed -$280K – 3456
2022
Q4 		$280K Buy
+11,344
New +$333K ﹤0.01% 2021

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dmitry Balyasny's INBX Position: Q4 2023 in Review

Dmitry Balyasny sold out of Inhibrx, Inc. Common Stock (INBX) in Q4 2023, closing a stake of 12,861 shares — an estimated $236K sold.

Dmitry Balyasny first reported a position in INBX in Q4 2022 and held it in 2 quarters. The position peaked at $280K in Q4 2022. 127 funds tracked by Wall St. Rank hold INBX as of Q4 2023.

  • Dmitry Balyasny reported no remaining Inhibrx, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Dmitry Balyasny sold 12,861 Inhibrx, Inc. Common Stock shares in Q4 2023, an estimated $236K.
  • Dmitry Balyasny first reported a position in Inhibrx, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Dmitry Balyasny's Inhibrx, Inc. Common Stock position peaked at $280K in Q4 2022.
  • 127 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.